REBECCA MEEK: Open Payments
NPI 1710160791 · AUGUSTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,002 in 37 payments from 23 companies in 2025. Trend: 2023 $113 · 2024 $407 · 2025 $2,002
Food & beverage: $1,825Education: $177
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 3 | $325 |
| PharmaEssentia USA Corporation | 2 | $151 |
| Ipsen Biopharmaceuticals, Inc | 1 | $142 |
| BeOne Medicines USA, Inc. | 2 | $141 |
| Otsuka America Pharmaceutical, Inc. | 1 | $137 |
| Daiichi Sankyo Inc. | 4 | $132 |
| AstraZeneca Pharmaceuticals LP | 2 | $128 |
| Novartis Pharmaceuticals Corporation | 5 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $122 |
| Novo Nordisk Inc | 1 | $121 |
Products named: RYBREVANT, BESREMI, Onivyde, BRUKINSA, REXULTI, CAPLYTA, Ozempic, Enhertu.
Industry payments across GA — which companies pay providers there.
